Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 22;13(1):16.
doi: 10.3390/cancers13010016.

A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer

Affiliations

A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer

Klara Hammarström et al. Cancers (Basel). .

Abstract

Radiotherapy (RT) or chemoradiotherapy (CRT) are frequently used in rectal cancer, sometimes resulting in complete tumor remission (CR). The predictive capacity of all clinical factors, laboratory values and magnetic resonance imaging parameters performed in routine staging was evaluated to understand what determines an excellent response to RT/CRT. A population-based cohort of 383 patients treated with short-course RT (5 × 5 Gy in one week, scRT), CRT, or scRT with chemotherapy (scRT+CT) and having either had a delay to surgery or been entered into a watch-and-wait program were included. Complete staging according to guidelines was performed and associations between investigated variables and CR rates were analyzed in univariate and multivariate analyses. In total, 17% achieved pathological or clinical CR, more often after scRT+CT and CRT than after scRT (27%, 18% and 8%, respectively, p < 0.001). Factors independently associated with CR included clinical tumor stage, small tumor size (<3 cm), tumor level, and low CEA-value (<3.8 μg/L). Size or stage of the rectal tumor were associated with excellent response in all therapy groups, with small or early stage tumors being significantly more likely to reach CR (p = 0.01 (scRT), p = 0.01 (CRT) and p = 0.02 (scRT+CT). Elevated level of carcinoembryonic antigen (CEA) halved the chance of response. Extramural vascular invasion (EMVI) and mucinous character may indicate less response to RT alone.

Keywords: Rectal cancer; chemoradiotherapy; comprehensive; population-based; radiotherapy; response prediction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of study cohort selection from the total cohort of 1220 rectal cancer patients diagnosed between 2010 and 2018 in two Swedish counties. Abbreviations: scRT = short-course radiotherapy; CRT = chemoradiotherapy; CT = chemotherapy; W&W = watch-and-wait.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curves of the four logistic regression models (solid lines) and reference ROC curves of the uninformative random classifier (dashed lines), annotated with area under curve (AUC) values and their 95% confidence intervals. (top left) Entire study cohort. (top right) scRT group. (bottom left) CRT group. (bottom right) scRT+CT group. Abbreviations: scRT = short-course radiotherapy; CRT = chemoradiotherapy; CT = chemotherapy.

References

    1. Glimelius B., Myklebust T.Å., Lundqvist K., Wibe A., Guren M.G. Two countries—Two treatment strategies for rectal cancer. Radiother. Oncol. 2016;121:357–363. doi: 10.1016/j.radonc.2016.11.010. - DOI - PubMed
    1. Glynne-Jones R., Wyrwicz L., Tiret E., Brown G., Rödel C., Cervantes A., Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017;28:iv22–iv40. doi: 10.1093/annonc/mdx224. - DOI - PubMed
    1. Habr-Gama A., Perez R.O., Nadalin W., Sabbaga J., Ribeiro U., Silva e Sousa A.H., Jr., Campos F.G., Jr., Kiss D.R., Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results. Ann Surg. 2004;240:711–717. doi: 10.1097/01.sla.0000141194.27992.32. - DOI - PMC - PubMed
    1. Ryan E.J., Warrier S.K., Lynch A.C., Heriot A.G. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review. Color. Dis. 2015;17:849–861. doi: 10.1111/codi.13081. - DOI - PubMed
    1. The 2017 European Society of Coloproctology (ESCP) Collaborating Group Evaluating the incidence of pathological complete response in current international rectal cancer practice: The barriers to widespread safe deferral of surgery. Colorectal Dis. 2018;20(Suppl. 6):58–68. doi: 10.1111/codi.14361. - DOI - PubMed

Grants and funding